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Abstract: The morphological, immunohistochemical, and immunopathological analyses of muscle biopsy are essen-
tial for the diagnosis of idiopathic inflammatory myopathies (IIMs). However, they are also one of the most common 
causes of misdiagnosis. Although several diagnostic criteria have been proposed for the diagnosis of IIMs, misdiag-
nosis still remains common in clinical practice. The present study aims to characterize the inflammatory profile of 
IIMs, including the expression of MHC-I, MHC-II, MAC and infiltrating cells. We also investigated the sensitivity and 
specificity of MHC-I and MHC-II immunostaining for the diagnosis of IIMs. We found that the expression of MHC-I 
and MHC-II was both higher in IIMs than in non-inflammatory myopathies (NIMs). The distribution of MHC-I in IIMs 
is different from that of MHC-II. MHC-I is mainly located in the sarcoplasms, while MHC-II is located mostly on the 
sarcolemmas. Moreover, our findings suggest that MAC may be a potential marker to diagnose DM, and the combi-
nation of MHC-I and MHC-II immunostaining results in a higher sensitivity and specificity for IIM diagnosis, especially 
for DM. In addition, infiltrating cells in PM were mainly CD8+ cells, but we found in DM and NIMs they were primarily 
CD4+ cells, which is consistent with previous studies. Lastly, glucocorticoid treatment and disease duration have 
little effect on the MHC-I and MHC-II expression pattern. Our findings indicate that the immunostaining of inflamma-
tory markers such as MHC-I, MHC-II, CD4, CD8, CD303 and MAC are of diagnostic value for IIMs regardless of the 
immunosuppression regime and disease duration.
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Introduction
The idiopathic inflammatory myopathies (IIMs) 
are a heterogeneous group of disorders com-
prised of dermatomyositis (DM), polymyositis 
(PM), inclusion body myositis (IBM), and necro-
tizing autoimmune myopathy [1-3]. The most 
remarkable myopathological feature of IIMs is 
the infiltration of inflammatory cells surround-
ing muscle fascicles or invading muscle fibers 
[4]. However, inflammatory infiltrates are not 
specific to IIMs and can be present in other 
genetic and acquired myopathies such as mus-
cular dystrophy and myasthenia gravis, which, 
if omitting the clinical pictures, may lead to the 
misdiagnosis of IIMs [5-7].
The 1975 Bohan and Peter criteria are still 
some of the most widely-used criteria in clinical 
practice [1, 2]. However, the criteria proposed 
in earlier times do not emphasize immunolo- 
gical characterization as part of the muscle 
pathology investigation, except for the Dalakas 
criteria [5], the first criteria introducing the 
profiling of inflammatory cells, in which CD8+ 
cells invading major histocompatibility complex 
(MHC) class I upregulated muscle fibers are 
used to define PM and thus significantly im- 
prove diagnostic specificity. The ENMC criteria 
[8] also use CD8+ cells invading non-necrotic 
fibers or ubiquitous MHC-I expression for PM 
diagnosis, and MAC deposition or perifascicular 
MHC-I expression for DM. However, one recent 
study shows that the CD8-MHC-I complex can 
also be present in PM, IBM and other unclassifi-
able myositis patients, which challenges the 
specificity of the CD8-MHC-I complex for PM 
[9]. Meanwhile, the distribution of MHC-I and 
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MHC-II molecules has seldom been evaluated 
in previous studies.
Immunological profiling of muscle biopsy holds 
significant diagnostic value and provides clues 
to pathogenesis. Firstly, both MHC-I and MHC-II 
are cell surface molecules whose major biolo- 
gical function is to present exogenous and 
endogenous antigens to immune cells. They are 
histochemically undetectable in normal human 
muscle fibers but upregulated in IIMs [10, 11]. 
Despite the generally accepted diagnostic 
value of ubiquitous or perifascicular expres-
sions of MHC-I and MHC-II in PM and DM, they 
were also found to be upregulated in other 
primary muscle disorders like muscular dystro-
phy, which compromises the specificity of 
MHC-I immunostaining for IIM diagnosis [12]. 
Secondly, the deposition of membrane attack 
complex (MAC) can be found in the blood ves-
sels, muscle fibers, and skin lesions of DM. 
MAC is believed to be involved in perimysial and 
perifascicular damage, which is the character-
istic histological change of perifascicular atro-
phy [13, 14]. Lastly, in DM, where the humoral 
mediated process is considered as the main 
pathogenic event, the inflammatory cells are 
predominantly CD4+ cells and B lymphocytes, 
while in PM, CD8+ cells invading MHC-I upregu-
lated muscle indicates cellular immunity is the 
core etiology [15, 16].
Although the expressions of MHC-I and MHC-II 
are emphasized in the diagnosis of IIMs, in our 
opinion, the diagnostic value of MHC-I and 
MHC-II may be underestimated. In the present 
study, we aim to determine the expression pat-
terns of MHC-I, MHC-II, MAC and inflammatory 
cells in PM, DM and non-inflammatory myopa-
thy (NIM) patients from our neuromuscular cen-
ter. Particular attention was also paid to the 
utility of distribution of MHC-I and MHC-II in dif-
ferentiating IIMs from NIMs. We also investi-
gated the effect of disease duration and gluco-
cases of IIMs and 18 cases of NIMs, in the 
neuromuscular center of Xiangya Hospital of 
Central South University from 2012 to 2016 
were included. The diagnosis of IIM was made 
according to the Bohan and Peter criteria [1, 2]. 
The IIM patients included 44 cases of PM and 
27 cases of DM, but no IBM cases were includ-
ed as the low number of patients might skew 
the statistical analysis. NIMs consisted of 12 
cases of dystrophinopathy and 6 of dysferlinop-
athy with secondary muscle inflammation, diag-
nosed based on pathological findings of muscle 
biopsy and/or genetic testing. In addition, 6 
cases that exhibited no muscle pathology 
changes and were devoid of any neuromuscular 
diseases were recruited as the normal control 
group. All patients provided written consent 
forms.
Muscle biopsies
Open muscle biopsies were taken from biceps 
brachii or gastrocnemius. The muscle samples 
were immediately frozen in isopentane cooled 
with liquid nitrogen and stored at -80°C. 
Subsequent routine histological and immuno-
histochemical analysis was performed on the 8 
µm cryostat sections.
Routine histological staining
Routine histological staining techniques in- 
cluded hematoxylin and eosin (H&E), modified 
Gömöri trichrome, acid phosphatase, periodic 
acid-Schiff (PAS), Oil red O, NADH-TR, ATPase 
(pH = 4.3, 4.6, 11.0), succinic dehydrogenase 
(SDH), and cytochrome C oxidase (COX).
Immunohistochemical staining
Sections were fixed for 10 minutes in acetone 
at -20°C, incubated in 0.3% H2O2 solution 
(Sigma) in phosphate-buffered saline (PBS 
0.01 M, pH 7.4, Sigma) for 10 minutes and sub-
sequently blocked in 10% fetal bovine serum 
Table 1. Antibodies employed in the present study
Antibody Species Dilution Company
MHC-I Mouse anti-human monoclonal 1:100 BioLegend
MHC-II Rabbit anti-human monoclonal 1:100 Abcam
CD4 Mouse anti-human monoclonal 1:100 BD Biosciences
CD8 Mouse anti-human monoclonal 1:200 BD Biosciences
CD303 Mouse anti-human monoclonal 1:100 BD Biosciences
MAC Mouse anti-human monoclonal 1:100 Abcam
corticoid on immunohistochemical 
staining in PM and DM.
Materials and methods 
Patients
With the approval of the Ethics 
Committee of Xiangya Hospital, 
Central South University, a total of 
89 Chinese patients, including 71 
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(Sigma) for 45 minutes. After the PBS wash, the 
samples were incubated with a primary anti-
body (Table 1) at 37°C for 3 hours. Then, they 
were rinsed in PBS and treated with a second-
ary antibody for 30 min at 37°C. An ABC kit was 
used (VECTASTAIN Elite ABC Kit PK-6100) 
according to the manufacturer’s recommenda-
tions, and the samples were treated with DAB 
(Sigma) for several minutes. Finally, the sec-
tions were sealed in neutral balsam. 
Light microscopy
All muscle samples were evaluated blindly by 
two experienced myopathologists. The patterns 
of MHC-I and MHC-II staining were categorized 
as sarcolemmal and sarcoplasmic. Moreover, 
sarcolemmal staining was classified as being 
completed sarcolemmal or partial sarcolem-
mal, depending on whether it involved the 
entire surface of the myofibers or was patchy in 
its distribution. The expression of MHC-I and 
MHC-II was assessed under at least six random 
different views of 200 magnification. The ratio 
of positively stained fibers to total non-necrotic 
myofibers was calculated. 
The quantification of CD4+ and CD8+ cells was 
assessed in at least six random microscopic 
fields at 200 magnification. The ratios of immu-
noreactive inflammatory cells to total inflamma-
tory cells in all the fields were calculated. The 
quantification of CD303+ plasmacytoid den-
dritic cells (pDCs) was performed with the hot 
spot method [17, 18] and used for myositis 
because of the relatively low frequency of in- 
flammatory cell infiltration. This method allows 
the quantification of cells in hot spots, defined 
as muscle areas containing the highest density 
of positive cells. Accordingly, six hot spots per 
muscle section were selected for CD303+ pDC 
quantification.
The patterns of MAC were classified as endo-
mysial, perimysial, capillary perivascular, or 
endomysial arteriolar and were assessed by 
Table 2. Clinical characteristics of each subgroup
Group Subgroup No. Male:female Age (year, Mean ± SEM)
Disease duration (month, 
Mean ± SEM)
CK (U/L,  
Mean ± SEM)
IIMs PM 44 9:13 44.6±2.2 15.2±3.7 2307.7±381.2
DM 27 1:2 36.5±3.9 8.5±2.1 4222.8±734.1
NIMs Dystrophinopathy 12 5:1 16.4±3.9 98.0±20.4 5205.8±912.6
Dysferlinoapthy 6 5:1 35.0±2.0 90.0±36.1 5528.8±901.5
Table 3. Average proportions of positive staining for MHC-I in each group
                    Position 
Group Sarcoplasmic (%) Sarcolemmal (%) Complete sarcolemmal (%) Partial sarcolemmal (%)
IIMs 71.8 61.9 35.6 26.3
NIMs 22.2 32.2 8.0 24.2
PM 62.0 50.2 24.9 25.3
DM 87.9 81.1 53.1 28.0
Dystrophinopathy 22.8 35.3 9.8 25.4
Dysferlinopathy 21.0 26.2 4.3 21.8
Table 4. Average proportions of positive staining for MHC-II in each group
                    Pattern 
Group Sarcoplasmic (%) Sarcolemmal (%) Complete sarcolemmal (%) Partial sarcolemmal (%)
IIMs 5.7 21.4 6.1 15.3
NIMs 1.6 4.8 2.3 2.5
PM 6.5 19.5 5.4 14.1
DM 4.5 24.4 7.3 17.2
Dystrophinopathy 0.7 1.8 0.5 1.3
Dysferlinopathy 3.5 10.8 5.8 5.0
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observing the whole section. The ratio of posi-
tively stained cases to the total cases was cal-
culated in each specific region. 
Data analysis
The Pearson chi-square (χ2) test was used 
to compare the frequency distribution of cate-
gorical variables. Student’s t-test or one-way 
ANOVA followed by Bonferroni’s post-hoc test 
were used to compare the mean values among 
various groups of cases and controls. The sta-
tistical analysis was performed using Stati- 
stical Package for Social Sciences (SPSS Inc., 
case with MHC-II immunopositivity in the 
absence of MHC-I staining. 
In terms of sarcolemmal staining, the pattern of 
MHC-I in the IIMs was more complete than par-
tial (P = 0.012), but it was more partial than 
complete in the NIMs (P = 0.000). MHC-I immu-
noreactivity in the IIMs was mainly in the sarco-
plasms instead of on the sarcolemmas (P = 
0.001). More specifically, MHC-I staining was 
more sarcoplasmic than sarcolemmal in PM (P 
= 0.001), while in DM, the staining of sarcolem-
mal MHC-I was more complete than partial (P = 
0.000). 
Figure 1. MHC-I and -II immunostainings. In PM (A, E), MHC-I staining was 
more sarcoplasmic while MHC-II immunoreactivity was mostly sarcolemmal. 
In DM (B, F), staining of sarcolemmal MHC-I was more complete than partial, 
and MHC-II immunostaining was mostly sarcolemmal. In NIMs (C, G), both 
MHC-I and MHC-II staining were mainly partial sarcolemmal. There was no 
immunoreactivity in normal control samples (D, H). (Original magnification 
×200, Scale bar = 300 μm).
Chicago, IL, USA) Version 20. A 
p-value <0.05 was considered 
statistically significant.
Results
Demographic and clinical 
features
There was a female predomi-
nance in IIM patients (male: 
female = 27:44), compared wi- 
th the male predominance in 
NIM (male:female = 5:1, P = 
0.001), which was partly due 
to the male dystrophinopathy 
patients. The CK levels of NIM 
patients were generally higher 
than those of IIMs (P = 0.023), 
while they were even higher in 
DM than in PM. Further details 
of the demographic statistics 
of the subgroups are listed in 
Table 2.
Patterns of MHC-I and MHC-II 
staining
All IIM and NIM cases showed 
MHC-I positive staining except 
for one PM patient, while on 
MHC-II staining, 70.4% of the 
IIMs and 22.2% of the NIMs 
showed positivity (P = 0.001). 
The average proportions of 
positive staining for MHC-I 
and MHC-II in IIMs, NIMs and 
each subgroup are shown in 
Tables 3, 4. There was no 
MHC-I or MHC-II immunoreac-
tivity in any of the normal con-
trol samples (Figure 1), and no 
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The MHC-II immunoreactivity in the IIMs was 
mostly sarcolemmal rather than sarcoplasmic 
(P = 0.000), and more partial than complete (P 
= 0.000). In the NIMs, there was no difference 
between the MHC-II sarcolemmal and sarco-
plasmic staining.
Diagnostic value of MHC-I and MHC-II
We used 35% and 20% as the cut-off points 
for the MHC-I sarcoplasmic and MHC-II partial 
sarcolemmal staining positivity respectively, 
which resulted in a sensitivity of 0.859 and a 
specificity of 0.833 for IIMs. To compare the 
DM with the NIMs, if MHC-I complete sarcolem-
mal staining was observed in more than 25% of 
the muscle fibers or MHC-II partial sarcolem-
mal staining in more than 22.5% of the muscle 
fibers, the sensitivity would be 0.963 and the 
specificity be 1.000 for DM. In the case of 
MHC-I sarcoplasmic staining being positive in 
more than 35% of the muscle fibers or MHC-II 
complete sarcolemmal staining in more than 
15.5% of the muscle fibers, the sensitivity and 
specificity of diagnosis of PM was 0.841 and 
0.833 respectively.
Given that one single index was used for IIMS 
diagnosis, MHC-I showed a better diagnostic 
value than MHC-II. For example, for the differ-
entiation of the DM from the NIMs, MHC-I had 
a sensitivity and a specificity as 0.926 and 
1.000 respectively, while MHC-II had only 0.778 
and 0.778 respectively. However, by combining 
MHC-I and MHC-II, the sensitivity and specifici-
ty for DM diagnosis was improved to 0.963 and 
1.000 respectively.
Profile of the infiltrating inflammatory cells
In PM, inflammatory cells were mainly located 
in clusters in the endomysium as well as the 
perimysium, whereas in DM, they were mainly 
perivascular and perifascicular. In NIMs, scat-
tered inflammatory cells were observed mainly 
in the endomysium and perimysium (Figure 2). 
The frequencies of inflammatory cells in all 
Figure 2. Inflammatory marker staining. In PM (A, E, I), inflammatory cells were mainly located in clusters in the 
endomysium, whereas in DM (B, F, J), they were mostly perivascular and perifascicular. In NIMs (C, G, K), scattered 
inflammatory cells were present mainly in the endomysium and perimysium. There were no inflammatory cells in the 
normal control group (D, H, L). (Original magnification ×200, Scale bar = 300 μm).
Table 5. Frequencies of inflammatory cells in 
IIMs and NIMs





IIMs 17.25 14.54 7.48
NIMs 8.61 3.44 3.22
PM 14.5 18.4 9.5
DM 21.7 8.2 4.2
Dystrophinopathy 7.8 2.8 1.4
Dysferlinopathy 10.3 4.7 6.8
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groups are listed in Table 5. No inflammatory 
cells were found in the normal control group. 
CD4+, CD8+ and CD303+ cells were more fre-
quent in IIMs than in NIMs (Figure 3). Moreover, 
CD8+ and CD303+ cells were more frequent 
in PM than DM (P<0.001, 0.01). In accordance 
with previous studies, the majority of the inflam-
matory cells in PM were CD8+ cells (P = 0.043), 
but CD4+ cells were the majority in DM and 
NIMs (P = 0.000, 0.000).
Immunohistostaining pattern of MAC
DM patients demonstrated more frequent cap-
illary perivascular MAC than PM patients (P = 
0.000). No NIMs showed MAC positivity on peri-
vascular spaces. The frequencies of MAC posi-
tive staining in all groups are listed in Table 6. 
No other significant difference was observed 
in the endomysial, perimysial, or endomysial 
arteriolar MAC staining patterns. On the basis 
of perivascular MAC staining in DM and other 
myopathies including PM and NIMs, MAC 
showed a sensitivity of 0.889 and specificity of 
0.903 to differentiate DM from other myopa-
thies. The normal control cases showed no 
MAC immunoreactivity (Figure 4).
Effects of disease duration and glucocorticoid 
on inflammatory profiles of PM and DM
Based on the disease duration upon the mus-
cle biopsy date, PM and DM patients were 
categorized into two groups respectively: the S 
group (duration shorter than three months) and 
the L group (duration longer than three months). 
PM-L consisted of 28 cases and PM-S 16, while 
DM-L included 19 cases and DM-S 8. The fre-
quencies of CD4+ and CD303+ cells were high-
er in DM-L than in DM-S (P = 0.003, 0.011). No 
other significant difference was identified in 
MHC-I, MHC-II and CD8+ T cells between PM-L 
and PM-S, or between DM-L and DM-S.
PM and DM patients were also divided into two 
groups depending on the usage of glucocorti-
coid: GC (glucocorticoid used in the 4 weeks 
before biopsy) and NGC group (no glucocorti-
coid used in the 4 weeks before biopsy). 
Figure 3. Proportions of inflammatory cells in IIMs and NIMs. CD4+, CD8+ and CD303+ cells were more frequent 
in IIMs than in NIMs (A). In PM (B), the majority of inflammatory cells were CD8+ cells. In DM (C) and NIMs (D), 
inflammatory cells were mainly CD4+ cells. The mean and SEM of the samples are indicated. *P<0.05, **P<0.01, 
***P<0.001.
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PM-NGC consisted of 37 cases and PM-GC 7 
cases, DM-NGC 19 cases and DM-GC 8 cases. 
There was no significant difference in MHC-I, 
MHC-II and inflammatory cell subtypes between 
PM-GC and PM-NGC, or between DM-GC and 
DM-NGC group.
Profile of MHC-I, MHC-II and infiltrating inflam-
matory cells between isolated IIMs and overlap 
IIMs
The IIM patients were classified into two groups 
based on whether or not they were associated 
with connective tissue diseases (CTDs) at the 
time of muscle biopsy: isolated IIMs and over-
lap IIMs. The overlap IIMs composed of five 
cases, including three DM patients associated 
with rheumatoid arthritis, one DM patient with 
systemic sclerosis, and one PM patient with 
systemic lupus erythematosus. The overlap 
IIMs accounted for 7.0% of all the IIMs, in which 
plasms, we find that MHC-I and MHC-II are good 
diagnostic markers in combination to diagnose 
IIMs with a sensitivity and specificity both high-
er than 0.833. For DM diagnosis, the sensitivity 
and specificity are both higher than 0.963, 
which is relatively high compared with previous 
studies [11, 12]. The distribution of MHC-I and 
MHC-II immunoreactivity in IIMs and NIMs was 
also different in our research. In IIMs, MHC-I is 
mostly expressed in sarcoplasms, while MHC-II 
is basically expressed in sarcolemmas. No sig-
nificant difference was identified on the MHC-I 
and MHC-II distribution of sarcoplasms and 
sarcolemmas in NIMs. Our study is the first to 
report and quantify the distribution of MHC-I 
and MHC-II in IIMs muscles for IIM diagnosis. 
The percentages of CD4+, CD8+ and CD303+ 
cells in IIMs are higher than those in NIMs in 
our research, which suggests that the inflam-
mation in dystrophinopathy and dysferlinopa-










PM 54.5 15.9 13.6 36.4 93.2
DM 33.3 29.6 88.9 37.0 92.6
Dystrophinopathy 8.3 8.3 0.0 8.3 41.7
Dysferlinopathy 83.3 0 0.0 66.7 83.3
Figure 4. MAC immunostaining. PM showed perimysial immunoreactivity, 
DM showed arteriolar staining, NIMs showed non-specific necrotic fiber im-
munostaining, and the normal control cases showed no MAC immunoreac-
tivity. (Original magnification ×200, Scale bar = 300 μm). 
the overlap DMs were 14.8% 
of the DMs and the overlap 
PMs were 2.3% of the PMs in 
our study. No significant differ-
ence was detected in MHC-I, 
MHC-II and inflammatory cell 
subtypes either between iso-
lated IIMs and overlap IIMs, 
or between isolated DM and 
overlap DM group.
Discussion
In the present study, the pat-
terns of sarcolemmal and sar-
coplasmic staining of MHC-I 
and MHC-II in non-necrotic 
myofibers were evaluated qu- 
alitatively. The sarcolemmal 
staining pattern was further 
categorized as complete or 
partial. The salient point of our 
study is that by quantifying 
MHC-I and MHC-II staining in 
the sarcolemmas and sarco-
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thy is more likely a secondary immune response 
to muscle damage. It has long been established 
that interstitial and perivascular inflammation 
in PM are predominantly CD8+ cells, and in DM 
CD4+ cells [15, 16]. In comparison, CD4+ cell-
predominant focal inflammatory infiltrates can 
sometimes be found on muscle biopsies of 
dysferlinopathy [19, 20]. In our study, CD8+ 
cells are the major inflammatory cells in PM, 
and CD4+ cells are most abundant in DM and 
NIMs. These findings again support the conclu-
sion that cytotoxicity mediates muscle fiber 
injuries in PM and the humoral immunity in DM. 
Dendritic cells (DCs) are professional antigen-
presenting cells supporting adaptive and innate 
immune responses [21]. They can be divided 
into two types: myeloid DCs (mDCs) involved in 
specific adaptive immune response and plas-
macytoid DCs (pDCs) which have a key role in 
innate immunity. pDCs are found mainly in DM 
while mDCs predominate in PM and IBM [22, 
23]. In the present study, CD303+ pDCs are 
more frequent in PM than DM, which is contrary 
to previous findings. This may be due to the fol-
lowing reasons. Firstly, the hot spot method of 
CD303+ pDCs calculation in our study was dif-
ferent from the quantification method used in 
previous studies. Secondly, CD303+ pDCs in 
DM showed a more scattered distribution in the 
perimysium than in PM in our study, combined 
with the hot spot method for CD303+ pDCs 
quantification, hence in our study the percent-
age of CD303+ pDCs in PM is higher than DM. 
Lastly, the immune response in Chinese IIMs 
may be different from that in other popula- 
tions. 
DM is considered a microangiopathy caused 
by MAC mediated complement cascade activa-
tion [24-27]. In our study, MAC positivity can 
be observed in the endomysium, perimysium, 
on the walls of intramuscular endomysial capil-
laries and arterioles in IIMs as well as NIMs. 
Taking distribution patterns into consideration, 
capillary and perivascular deposition of MAC in 
DM is much higher than in PM and NIMs. MAC 
deposition in the capillary walls of endomysial 
microvessels is deemed highly specific to DM, 
especially in childhood DM [13, 24]. However, 
one recent study by Braczynski [28] reports 
that the capillary MAC deposits’ diagnostic 
value may be overestimated for DM. In our 
study, although the microvessel MAC immu-
nopositivity is also detected in other myositis, 
endomysial capillary MAC immunopositivity for 
the diagnosis of DM gives a relatively high sen-
sitivity of 0.889 and specificity of 0.903. Thus, 
we confirm that capillary perivascular deposi-
tion of MAC can be used as an important part 
of the diagnostic workup for DM.
It has been shown that immunosuppressive 
treatment in IIMs has little effect on MHC-I 
expression, hence making MHC-I a useful diag-
nostic marker for IIMs regardless of previous 
treatment [29]. Recent studies have also dis-
covered that corticosteroid therapy has little 
influence on the presence or degree of inflam-
matory infiltrates in IIMs [30]. Our study shows 
that glucocorticoid treatment within 4 weeks 
before biopsy does not affect the immunoreac-
tivity of MHC-I and MHC-II, nor does it change 
the subtype of inflammatory cells. Moreover, 
we have shown that the disease duration also 
has little effect on the expression of MHC-I and 
MHC-II, which has not been reported before. 
This phenomenon suggests that the overex-
pression of MHC-I and MHC-II is sustained 
throughout the whole disease duration and 
plays an essential role in disease pathogene-
sis. Besides, the CD303+ pDCs in our study, at 
the late stage of DM, were higher than in the 
early stage, which refutes an initiation role of 
pDCs in DM etiology. 
In our study, IIMs are categorized into two 
groups: isolated and overlap. We find that there 
is no difference in the immunoreactivity of 
MHC-I, MHC-II and the subtype of inflammatory 
cells between the isolated and overlap groups 
in IIMs, which has been only rarely reported 
before. The underlying mechanism remains elu-
sive, but we consider these phenomena strong-
ly indicate a common immunologic pathogene-
sis between overlap and isolated IIMs [31].
In conclusion, our study shows that by the 
quantitative analysis of sarcolemmal and sar-
coplasmic staining, MHC-I and MHC-II are sen-
sitive and specific markers for IIM diagnosis, 
and especially for DM diagnosis. In addition, 
our findings indicate that regardless of the dis-
ease duration, the immunosuppression regime, 
or CTD overlapping, the immunohistochemical 
staining for inflammatory markers, such as 
MHC-I, MHC-II, CD4, CD8, CD303 and MAC, are 
of diagnostic value for IIMs.
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